...or the future of arthritis treatment and cardiovascular disease prevention?
Part Two: The Company's Position
As a reminder, I am long shares of ECYT.
Monday, June 30, 2014
Endocyte, the SMDC, and the future of clinical oncology...
...or the future of arthritis treatment and cardiovascular disease prevention?
Part One: The Premise
I'd like to take the time to disclaim here that I'm long Endocyte ($ECYT). I'm also ridiculously, unhealthily bullish about the prospects of this company in the next decade or two. Just so we get that out of the way: I'm going to try and make this the most fair and even-keeled assessment that I can, but be aware of my stance toward this company. Now that that's out of the way, onto the show!
Part One: The Premise
I'd like to take the time to disclaim here that I'm long Endocyte ($ECYT). I'm also ridiculously, unhealthily bullish about the prospects of this company in the next decade or two. Just so we get that out of the way: I'm going to try and make this the most fair and even-keeled assessment that I can, but be aware of my stance toward this company. Now that that's out of the way, onto the show!
Saturday, June 28, 2014
The Keeping of the Record
In order for this to be the most maximal learning experience, I'm going to be adding a 'model portfolio' of what I would do if I was only going to invest in pharmaceutical companies based on the information that I've presented here, just so that I have something to keep myself intellectually honest about my efforts.
This 'model portfolio' is definitely, DEFINITELY not an exhortation to follow any of the trades/investment theses presented during my time on this blog, it's just a way for me to keep track of myself. Hopefully it'll teach me about biotech investing, without me having to actually risk a substantial amount of capital to learn the same lesson. Of course, nothing is the same as when you get to "the real deal", but I think it can still be a good developmental tool for myself. I'll also post it on here once I find a way to permalink it to the front page, so that other people can watch my progress/success/failure as it happens!
Happy Investing!
JVS
This (and the eventual model portfolio) is not a trade recommendation, or a financial recommendation of any kind.
 |
| Me, after my stunningly prescient biotech stock picks. (lol) |
This 'model portfolio' is definitely, DEFINITELY not an exhortation to follow any of the trades/investment theses presented during my time on this blog, it's just a way for me to keep track of myself. Hopefully it'll teach me about biotech investing, without me having to actually risk a substantial amount of capital to learn the same lesson. Of course, nothing is the same as when you get to "the real deal", but I think it can still be a good developmental tool for myself. I'll also post it on here once I find a way to permalink it to the front page, so that other people can watch my progress/success/failure as it happens!
Happy Investing!
JVS
This (and the eventual model portfolio) is not a trade recommendation, or a financial recommendation of any kind.
Update on Galectin Therapeutics ($GALT):
Preclinical Trial Reassuring, if Little Else
Disclaimer: the author is no longer long shares or options of $GALT, but is considering entering a small position the next month.
Disclaimer: the author is no longer long shares or options of $GALT, but is considering entering a small position the next month.
Monday, Galectin Therapeutics announced the results of a small preclinical study. You can read about the results from their investor relations website. You can also click here to see my previous take on Galectin Therapeutics. There are definitely some large positives in their brief press release, along with a few questions I'm left with. Hit the jump for my take on what the preclinical trial means.
I'm Baaaaaack
Hey everyone, sorry for the complete (literal) dearth of posts in the last 3 months; med school finals and summer lab rotations started to get way too busy, and interfered with my first love: investing!
So, I'm really going to try hard to make this at least a biweekly (if not weekly) blogging foray. Tomorrow or Monday I'm going to post my thoughts on a biotech position that I'm currently in, one that I wish I had waited to enter until this week. Hopefully I can illuminate why in the upcoming post. I truly think it's a robust opportunity, for a company that I am expecting to hold for AT LEAST 5-10 years. Let's discuss.
So, I'm really going to try hard to make this at least a biweekly (if not weekly) blogging foray. Tomorrow or Monday I'm going to post my thoughts on a biotech position that I'm currently in, one that I wish I had waited to enter until this week. Hopefully I can illuminate why in the upcoming post. I truly think it's a robust opportunity, for a company that I am expecting to hold for AT LEAST 5-10 years. Let's discuss.
Friday, April 4, 2014
Galectin Therapeutics: Some more thoughts
Disclaimer: I'm long $GALT with a small position, and considering adding a bit more due to recent downswing in prices in $IBB.
So, I finally have some time to sit down and give some more analysis on $GALT, whose Phase I trial I wrote a snap-reaction to earlier in the week here. Give that a read, and then come back here.
VS . 
One of the funny things that I've been reading about that seems to be a prevailing opinion from retail investors is that GALT, with a successful Phase II (or even Phase I) trial of GR-MD-02, deserves a market cap valuation identical to ICPT's ~ $6B. This is ludicrous for a few reasons.
So, I finally have some time to sit down and give some more analysis on $GALT, whose Phase I trial I wrote a snap-reaction to earlier in the week here. Give that a read, and then come back here.
VS . One of the funny things that I've been reading about that seems to be a prevailing opinion from retail investors is that GALT, with a successful Phase II (or even Phase I) trial of GR-MD-02, deserves a market cap valuation identical to ICPT's ~ $6B. This is ludicrous for a few reasons.
Wednesday, April 2, 2014
What am I long?
Quick one for today. Someone asked earlier "What are you long/short?"
I'm currently not short any biotech stocks, although I'm considering one that I'll write on sometime this week.
Currently long:
Ariad Pharmaceuticals ($ARIA) -- sometime to come
Galectin Therapeutics ($GALT) -- detailed yesterday
I'm thinking I'll write some on ARIA sometime in the next few days (as my schedule allows); I hope to have something a little more substantive than what I put out for GALT. Both of these seem to have some underappreciated value. We'll see.
I'm also really interested in getting some short ideas in biotech out there; I'll detail why in a few days.
Happy investing!
JVS
EDIT: I had previously written that I was long SNTA, which is no longer true; I'm not even sure if it was at the time I wrote this note, because this period was shortly after I had begun to clean my portfolio of a lot of my biotech names that I was long. :-) This was due to a lot of factors, but mostly my massive overexposure to biotech names that I really had no rationale to invest in. I quickly realized that SNTA was also one of those, because I realized I didn't really know enough about the company to make a rational case for why I was invested. As such, I will not be writing anything on SNTA. -- update from 6-28-14
I'm currently not short any biotech stocks, although I'm considering one that I'll write on sometime this week.
Currently long:
Ariad Pharmaceuticals ($ARIA) -- sometime to come
Galectin Therapeutics ($GALT) -- detailed yesterday
I'm thinking I'll write some on ARIA sometime in the next few days (as my schedule allows); I hope to have something a little more substantive than what I put out for GALT. Both of these seem to have some underappreciated value. We'll see.
I'm also really interested in getting some short ideas in biotech out there; I'll detail why in a few days.
Happy investing!
JVS
EDIT: I had previously written that I was long SNTA, which is no longer true; I'm not even sure if it was at the time I wrote this note, because this period was shortly after I had begun to clean my portfolio of a lot of my biotech names that I was long. :-) This was due to a lot of factors, but mostly my massive overexposure to biotech names that I really had no rationale to invest in. I quickly realized that SNTA was also one of those, because I realized I didn't really know enough about the company to make a rational case for why I was invested. As such, I will not be writing anything on SNTA. -- update from 6-28-14
Subscribe to:
Posts (Atom)